Gene · 6144
RPL21: ribosomal protein L21
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL21: ribosomal protein L21. Genes, record 6144. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6144
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P46778 | Large ribosomal subunit protein eL21 | 160 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents45
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62001 | P46778 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62002 | P46778 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62003 | P46778 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62004 | P46778 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6908 | P46778 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6908 | P46778 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73996 | P46778 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73997 | P46778 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73998 | P46778 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73999 | P46778 | Espacenet |
1 to 10 of 45
See all 45 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants500
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL21 papers | Newest fiscal year |
|---|---|---|---|
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P20GM121176 | Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2. | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 2 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 2 | 2025 |
| P30CA124435 | Stanford Cancer Institute | 2 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 2 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 2 | 2025 |
| R01HD086634 | Specialized Translational Control of Stem Cell Differentiation and Embryonic Development | 2 | 2025 |
| ZIAAG000393 | Influence of Post-transcriptional Gene Regulation on Cell Senescence and Aging | 2 | 2025 |
1 to 10 of 500Source NIH's project files
See all 500 nih grantsPapers644
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-omics Mendelian randomization identifies mitochondrial genes associated with immune microenvironment signatures in endometriosis. | Front Reprod Health | 2026 | 42157969 | PubTator, text mining | PubMed |
| Identification of ribosomal protein eL21 as a novel externalized protein and a target in triple-negative breast cancer. | Cancer Gene Ther | 2026 | 41957522 | PubTator, text mining | PubMed |
| Aerobic sister lineage of breviates has gene-rich mitochondrial genomes. | Curr Biol | 2026 | 41831440 | PubTator, text mining | PubMed |
| Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma. | J Immunother Cancer | 2026 | 41617396 | PubTator, text mining | PubMed |
| Integrative Analysis of the Role of MRPL21 in Human Pan-Cancer and Its Relationship with the Progression of Lung Adenocarcinoma. | Mol Biotechnol | 2026 | 39775548 | PubTator, text mining | PubMed |
| Multi-omics identification of immune-related biomarkers predicting tofacitinib response in rheumatoid arthritis. | Front Immunol | 2025 | 41668767 | PubTator, text mining | PubMed |
| LTO1 and YAE1 regulate MHC-I expression via nonsense-mediated RNA decay in tumor cells. | J Immunother Cancer | 2025 | 40987494 | PubTator, text mining | PubMed |
| Triglycerides and T Cells in Cardiovascular Risk: Inflammatory Transcriptomic Profile in Hypertriglyceridemia Patients' T Cells. | JACC Basic Transl Sci | 2025 | 40845480 | PubTator, text mining | PubMed |
| Identifying Molecular Modulators of the Vascular Invasion in Rectal Carcinoma: Role of ADAMTS8 and Its Co-Dependent Genes. | Int J Mol Sci | 2025 | 40650042 | PubTator, text mining | PubMed |
| adverSCarial: assessing the vulnerability of single-cell RNA-sequencing classifiers to adversarial attacks. | Bioinformatics | 2025 | 40234247 | PubTator, text mining | PubMed |
1 to 10 of 644
See all 644 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6144
GET https://conductscience.org/api/genes/v1/6144/patents?page=2